Anti-Human ErbB2/Her2 Recombinant Nanobody (11A4) (HY286053)

Name: Anti-Human ErbB2/Her2 Recombinant Nanobody (11A4)
Brand: abinScience
SKU: HY286053
Price: 126 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

20ug
50ug
100ug
1mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo

HY286053

Descripción

Anti-Human CD340/ERBB2/HER2 Nanobody (11A4) [11A4] (HY286053) is a alpaca monoclonal antibody detecting ERBB2 in ELISA. Suitable for Human.

Reactividad de especies

Human

Aplicaciones

ELISA

Especie huésped

Alpaca

Clonalidad

Monoclonal

Isotipo

VHH-8His-Cys-tag

ID de clon

11A4

Objetivo

CD340, EC:2.7.10.1, ERBB2, HER2, MLN 19, MLN19, Metastatic lymph node gene 19 protein, NEU, NGL, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Receptor tyrosine-protein kinase erbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2

Nivel de endotoxinas

< 10 EU/mg

Pureza

>95% as determined by SDS-PAGE.

Purificación

Purified by Nickel column.

Número de acceso

P04626

Forma

Liquid

Buffer de almacenamiento

0.01M PBS pH 7.4.

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Información de uso del producto

Aplicación	Dilución
ELISA	1:2000-1:20000

Estabilidad y almacenamiento

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Fondo

Receptor tyrosine-protein kinase erbB-2 (CD340/ERBB2) is a ~137 kDa protein. Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. CD340 is the therapeutic target of trastuzumab (Herceptin) and trastuzumab deruxtecan (Enhertu).

Nota

For research use only.

Imágenes